CTNI-52. SURVIVAL OUTCOMES IN RECURRENT GLIOBLASTOMA (RGBM) PATIENTS TREATED WITH A SINGLE INTRA-TUMORAL ADMINISTRATION OF BIZAXOFUSP, AN IL-4R-TARGETING TOXIN, IN A PHASE IIB TRIAL
John Sampson, Achal Singh Achrol, Manish Aghi, Krystof Bankiewicz, Martin Bexon, Steven Brem, Andrew Brenner, Sajeel Chowdhary, Melissa Coello, Annick Desjardins, Benjamin Ellingson, John Floyd, Seunggu Han, Santosh Kesari, Yael Mardor, Fahar Merchant, Rosemina Merchant, Dina Randazzo, Michael A Vogelbaum, Frank Vrionis, Eva Wembacher-Schroeder, Minh D To, Miroslaw Zabek, Nicholas Butowski
This research output has an Altmetric Attention Score of 301. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2023.
All research outputs
#110,653
of 24,829,155 outputs
Outputs from Neuro-Oncology
#14
of 3,462 outputs
Outputs of similar age
#996
of 200,222 outputs
Outputs of similar age from Neuro-Oncology
#1
of 39 outputs
Altmetric has tracked 24,829,155 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,462 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,222 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.
